Lobe Sciences Ltd. LOBEF
OTC PK
| 05/31/2026 | 02/28/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -32.60% | 172.51% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -50.69% | 67.30% | |||
| Operating Income | 50.69% | -67.30% | |||
| Income Before Tax | 52.19% | -85.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 52.19% | -85.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 1.20% | 57.69% | |||
| Net Income | 70.29% | -97.76% | |||
| EBIT | 50.69% | -67.30% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 70.83% | -92.00% | |||
| Normalized Basic EPS | 87.50% | -118.18% | |||
| EPS Diluted | 70.83% | -92.00% | |||
| Normalized Diluted EPS | 87.50% | -118.18% | |||
| Average Basic Shares Outstanding | 3.07% | 0.86% | |||
| Average Diluted Shares Outstanding | 3.07% | 0.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||